@NetworkPrcsg profile picture
PRCSG_network @NetworkPrcsg

The mission of the PRCSG is to conduct high quality clinical trials, of therapeutic agents, in children with rheumatic diseases.

Joined April 2022
  • Tweets 72
  • Following 93
  • Followers 90
Photos and videos
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial - Brunner - 2026 - Arthritis & Rheumatology - Wiley Online Library acrjournals.onlinelibrary.wi…

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a...

Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health-related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient-reported outcomes (PROs)...

acrjournals.onlinelibrary.wiley.com
1
13
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial - Brunner - Arthritis Care & Research - Wiley Online Library acrjournals.onlinelibrary.wi…

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With...

Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythe...

acrjournals.onlinelibrary.wiley.com
8
PRCSG_network retweeted
Arthritis Foundation@ArthritisFdn
22 Sep 2025
🎄 Lace up & save! The Jingle Bell Run is coming, and now’s your chance to join in for less. Use code FALL for $5 off registration — limited time only! 🏃‍♀️❄️ Run for fun. Run for a cause. 👉 arthr.org/4lT6Cy2 #JingleBellRun
5
7
408
"Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting" — Read it on @ResearchGate: researchgate.net/publication…

Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and...

Request PDF | Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting | Objective To...

researchgate.net
11
25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges - Shishov - 2025 - Arthritis Care & Research - Wiley Online Library acrjournals.onlinelibrary.wi…

25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and...

There are over 100 rheumatic diseases and approximately 300,000 children with a pediatric rheumatic disease (PRD) in the United States. The most common PRDs are juvenile idiopathic arthritis (JIA),...

acrjournals.onlinelibrary.wiley.com
1
13
frontiersin.org/journals/med…

Frontiers | New medicines for childhood-onset systemic lupus erythematosus: an EU perspective on...

Childhood-onset systemic lupus erythematosus (cSLE, also known as juvenile or paediatric SLE) is a severe autoimmune disease affecting multiple organs and sy...

frontiersin.org
14
Clinically Inactive Disease and Remission in Patients with Juvenile Idiopathic Arthritis Receiving Tofacitinib: Pos… pubmed.ncbi.nlm.nih.gov/4031…

Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving...

In patients with JIA receiving tofacitinib, JADAS10-CID and ACR-CID rates improved rapidly and were sustained over time, and a small proportion of patients achieved JADAS10 remission. Inactive...

pubmed.ncbi.nlm.nih.gov
17
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations… pubmed.ncbi.nlm.nih.gov/3995…

Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based...

The task force developed consensus-based recommendations when scoring the PhGA in nonsystemic and systemic JIA. These recommendations will lead to more reliable scoring of disease activity in...

pubmed.ncbi.nlm.nih.gov
17
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Ar… pubmed.ncbi.nlm.nih.gov/3913…

Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course...

Among the CBBs included, only resistin was significantly associated with treatment response, and no CBB was identified that forecasts JIA improvement after initiation of tofacitinib. The association...

pubmed.ncbi.nlm.nih.gov
15
Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis acrabstracts.org/abstract/ef…

Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis -...

Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here we report...

acrabstracts.org
17
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study acrabstracts.org/abstract/ph…

Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World...

Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study of...

acrabstracts.org
15
Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients with Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐label, Phase 1 Trial - Brunner - Arthritis Care & Research - Wiley Online Library acrjournals.onlinelibrary.wi…

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐C...

Objective This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular-course juvenile idiopathi...

acrjournals.onlinelibrary.wiley.com
22
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction - Eloseily - Arthritis Care & Research - Wiley Online Library acrjournals.onlinelibrary.wi…

Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications...

Objective To assess changes in gene expression following tofacitinib treatment and investigate transcription patterns as potential predictors of treatment response in patients with active juvenile...

acrjournals.onlinelibrary.wiley.com
27
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study jrheum.org/content/51/11/112…

Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-T...

Objective To report pharmacokinetics (PK), immunogenicity, clinical effect, and safety of intravenous (IV) golimumab in children with active polyarticular-course juvenile idiopathic arthritis (pcJIA)...

jrheum.org
3
3
82
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthrit… pubmed.ncbi.nlm.nih.gov/3891…

S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile...

Lower baseline levels of S100A8/9 and S100A12 proteins predicted better response to abatacept treatment than higher levels and may serve as early predictive biomarkers in pJIA. Decreases in these...

pubmed.ncbi.nlm.nih.gov
16
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary re… pubmed.ncbi.nlm.nih.gov/3884…

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthrit...

NCT01500551.

pubmed.ncbi.nlm.nih.gov
1
17
We invite you to join us for a late breaking poster presentation on Safety and Efficacy of tofacitinib with sJIA @ACRheum on November 18. Poster L09: November 18, 2024, 10:30 AM – 12:30 PM, Poster Session C, (L01-L14) Late Breaking Posters
1
1
73
We invite you to join us for a poster presentation on PK of ustekinumab in Juvenile Psoriatic Arthritis @ACRheum on November 16. Poster 0384: November 16, 2024, 10:30 AM – 12:30 PM, Poster Session A, Pediatric Rheumatology – Clinical Poster I
1
1
73
Dr. Ekemini Ogbu Named Chair of ACR Pediatric Rheumatology Committee oaacd.wordpress.com/2024/08/…

Dr. Ekemini Ogbu Named Chair of ACR Pediatric Rheumatology Committee

Congratulations to Dr. Ekemini Ogbu on being elected the chair of the American College of Rheumatology’s (ACR) Committee on Pediatric Rheumatology! This committee focuses on “…adv…

oaacd.wordpress.com
1
28
Intravenous Golimumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis: Long-term Extension of an Open-label, Phase 3 Study jrheum.org/content/early/202…

Intravenous Golimumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis: Long-t...

Objective Report pharmacokinetics, immunogenicity, clinical effect, and safety of intravenous golimumab in children with active polyarticular-course juvenile idiopathic arthritis (pcJIA) who partic...

jrheum.org
16
Load more